All articles tagged with #cabotegravir
Campaigners in Northern Ireland are advocating for the introduction of cabotegravir injections, a long-acting HIV prevention drug, to help meet the goal of ending new HIV cases by 2030, with the drug already being adopted in England, Wales, and Scotland as an alternative to daily PrEP pills.
ViiV Healthcare has developed a new, stronger form of the HIV prevention drug cabotegravir, which could be administered as an injection every four months. The new formulation, called "cabotegravir ultra long-acting" (CAB-ULA), showed promising results in a trial, with fewer side effects and longer-lasting effects compared to the current form of the drug. If further trials are successful, this new long-acting injection could revolutionize HIV prevention and treatment.
The rollout of long-acting injectable cabotegravir (CAB-LA) as pre-exposure prophylaxis (PrEP) for HIV without delay can have a significant impact on the HIV epidemic, particularly in settings with high HIV incidence. A study showed that CAB-LA was superior to the daily oral regimen in preventing HIV infection. By expanding PrEP coverage with CAB-LA, the projected HIV incidence decreased in simulation models for Atlanta, Montreal, and the Netherlands. Increasing PrEP coverage by 11 percentage points by 2032 could lead to a reduction of over 45% in new HIV acquisitions. Offering CAB-LA to current and prospective PrEP patients could improve adherence and increase the effectiveness of HIV prevention.